• You need to sign in or sign up before continuing.
Close
Announcements
Projects
Orgs
Project Post
Articles 130
Votes 0
Endpoints News

Authors 22

Max Gelman
Tyler Patchen
Lei Lei Wu
Amber Tong
John Carroll
Zachary Brennan
Kyle LaHucik
Nicole DeFeudis
Paul Schloesser
Katherine Lewin
Beth Snyder Bulik
Katherine
Andrew Dunn
Drew Armstrong
Ryan Cross
Jared Whitlock
Reynald Castañeda
Jaimy Lee
Ayisha Sharma
Anna Brown
Lia DeGroot
ENDPOINTS
FDA approves Vertex and CRISPR's Casgevy as first CRISPR-edited therapy for beta-thalassemia - Endpoints News
>1y
Doudna's new venture; Aclaris CEO to step down; Tome's $114M liver disorder deal with Genevant - Endpoints News
>1y
The Bell Labs of biotech: Stuart Schreiber has billionaire support for new biomedical institute - Endpoints News
>1y
Novartis doubles down on neurologic gene therapy work with Voyager - Endpoints News
>1y
Grail has big plans for its blood cancer tests. The first step: Finding a new owner - Endpoints News
>1y
Lilly, Novo's bet on heart disease starts to take shape, and 2024 could be a pivotal year for their GLP-1s - Endpoints News
>1y
Structure's oral GLP-1 a 'work in progress' following Phase IIa obesity and diabetes data - Endpoints News
>1y
Feng Zhang's latest gene editing trawl reels in 188 new CRISPR systems - Endpoints News
>1y
Q32 Bio to take Homology Medicines' Nasdaq spot to fund PhII trials in autoimmune, inflammatory conditions - Endpoints News
>1y
Anthos' blood thinner cuts the risk of bleeding amid race to develop safer anticoagulants - Endpoints News
>1y
Alnylam's longer-term RNAi treatment lowers blood pressure in mid-stage study - Endpoints News
>1y
Project to create yeast with fully synthetic genome nears completion - Endpoints News
>1y
Pfizer details mRNA flu vaccine data, but revises timeline - Endpoints News
>1y
Lilly makes another move for Verve's genetic medicines, this time buying Beam's opt-in rights - Endpoints News
>1y
FDA approves Junshi, Coherus’ PD-1 toripalimab for nasopharyngeal carcinoma - Endpoints News
>1y
Sanofi will spin out consumer unit, putting weight behind R&D efforts: 'I have to invest in the science now' - Endpoints News
>1y
Biogen, GSK, Novo Nordisk and five other biopharmas land on annual list of best inventions for 2023 - Endpoints News
>1y
Amgen to cut 350 staffers following $28B Horizon takeover - Endpoints News
>1y
ESMO embargo break leads cancer conference to release data for Bristol Myers, J&J, Novartis, AstraZeneca - Endpoints News
>1y
Gilead spends $100M to partner with Assembly Bio on antivirals for hepatitis, herpes - Endpoints News
>1y
Sanofi’s atopic dermatitis drug amlitelimab hits primary endpoint, on its way to PhIII trial - Endpoints News
>1y
Moderna's new Covid-19 vaccine analysis 'giving weight' to annual boosting interval, company says - Endpoints News
almost2y
Hamas strikes could impact some biopharma operations in Israel - Endpoints News
almost2y
FDA rejects Alnylam's Onpattro label expansion after adcomm voted in favor - Endpoints News
almost2y
Discounts for weight loss drugs are estimated at more than half, fueling questions about price, PBMs and coverage - Endpoints News
almost2y